



July 1, 2026

Company name	Japan Medical Dynamic Marketing, INC.
Name of representative	Toshiyuki Hironaka President and Representative Director (Securities code: 7600 ; Tokyo Stock Exchange Prime)
Inquiries	Shinji Munechika General Manager, Investor Relations Office Telephone: +81-3-3341-6705

Notice of Additional Regulatory Approval for China-Made Artificial Hip Joint Products by China WOMA and Commencement of Sales in the Chinese Market

Changzhou Waston Ortho Medical Appliance Co., Limited (“WOMA”), a joint venture established in the People’s Republic of China (“China”) and located in Changzhou, Jiangsu Province, announces that, in addition to the "Regulatory Approval for Artificial Hip Joint Products" disclosed on June 12, 2026, the company has newly obtained regulatory approval from the National Medical Products Administration (NMPA) for additional China-manufactured artificial hip joint products.


As a result, in addition to its China-manufactured artificial hip joint products that have already obtained regulatory approval, WOMA plans to begin sales of the newly approved products in the Chinese market as well.

1. Artificial Hip Joint Products Approved for Regulatory Approval

· Product Names:

- ① Entrada Stem Collarless (Chinese: 无领型股骨柄, English: Hydroxylapatite coating collarless femoral stem)
- ② Entrada Stem Collared (Chinese: 有领型股骨柄, English: Hydroxylapatite coating collared femoral stem)
- ③ Femoral Head (Chinese: 陶瓷球头, English: Ceramic Head)
- ④ Escalade Cup (Chinese: 髌臼杯, English: Acetabular Cup)
- ⑤ Escalade Liner (Chinese: 髌臼内衬, English: Acetabular Liner)

- Medical Device Approval Number: 国械注准 20263131244
- Intended Use: Artificial hip joint system



2. Sales Launch Schedule in China

- By the end of October 2026: Completion of manufacturing of artificial hip joint products and preparation of sales inventory (planned)
- December 2026: Scheduled sales launch

3. Future Outlook

With the addition of the "Entrada Hip Stem" series of products to the previously approved "OVATION Hip Stem" series in China, we are now able to offer healthcare professionals a broader range of product options.

Our group will continue to work to expand sales of artificial joint products in the Chinese market through WOMA, while also further strengthening our business foundation in China going forward.

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.